• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

8.210 -0.110 (-1.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,024,296
Open 8.290
Bid (Size) 8.200 (200)
Ask (Size) 8.320 (100)
Prev. Close 8.320
Today's Range 8.170 - 8.380
52wk Range 7.210 - 21.53
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
June 13, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 12, 2026
From Robbins Geller Rudman & Dowd LLP
Via Business Wire

Performance

YTD
-54.1%
-54.1%
1 Month
-3.4%
-3.4%
3 Month
-48.2%
-48.2%
6 Month
-58.4%
-58.4%
1 Year
-60.5%
-60.5%

More News

Read More
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
June 12, 2026
Via Newsfile
Topics Lawsuit
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
June 12, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
June 12, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
June 12, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 11, 2026
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
June 11, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
June 11, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
June 11, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
June 11, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
June 11, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law
June 11, 2026
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit
June 10, 2026
From Robbins LLP
Via Business Wire
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
June 10, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ADMA Biologics, Inc. Investors – ADMA
June 10, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 26, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 22, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
May 22, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
May 21, 2026
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
May 21, 2026
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
May 08, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire

Frequently Asked Questions

Is ADMA Biologics Inc - Common Stock publicly traded?
Yes, ADMA Biologics Inc - Common Stock is publicly traded.
What exchange does ADMA Biologics Inc - Common Stock trade on?
ADMA Biologics Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ADMA Biologics Inc - Common Stock?
The ticker symbol for ADMA Biologics Inc - Common Stock is ADMA on the Nasdaq Stock Market
What is the current price of ADMA Biologics Inc - Common Stock?
The current price of ADMA Biologics Inc - Common Stock is 8.210
When was ADMA Biologics Inc - Common Stock last traded?
The last trade of ADMA Biologics Inc - Common Stock was at 06/12/26 04:00 PM ET
What is the market capitalization of ADMA Biologics Inc - Common Stock?
The market capitalization of ADMA Biologics Inc - Common Stock is 1.61B
How many shares of ADMA Biologics Inc - Common Stock are outstanding?
ADMA Biologics Inc - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap